Nifty
Sensex
:
:
11844.10
39434.72
187.05 (1.60%)
623.33 (1.61%)

Pharmaceuticals & Drugs

Rating :
58/99

BSE: 500087 | NSE: CIPLA

570.60
5.85 (1.04%)
24-May-2019 | 3:57PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  569.20
  •  572.50
  •  559.45
  •  564.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1796355
  •  10250.00
  •  678.45
  •  483.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 45,955.50
  • 30.08
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 49,087.94
  • 0.53%
  • 3.06

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.70%
  • 4.03%
  • 16.13%
  • FII
  • DII
  • Others
  • 1.02%
  • 13.67%
  • 28.45%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.82
  • 8.30
  • 3.69

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.26
  • 5.79
  • 2.65

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.25
  • 0.18
  • 0.99

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.04
  • 37.11
  • 38.25

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.70
  • 3.82
  • 3.44

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.43
  • 18.63
  • 17.90

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
4,403.98
3,697.97
19.09%
4,007.54
3,913.82
2.39%
4,011.90
4,082.41
-1.73%
3,938.99
3,525.05
11.74%
Expenses
3,442.93
3,141.10
9.61%
3,299.87
3,095.16
6.61%
3,309.68
3,278.02
0.97%
3,212.62
2,878.59
11.60%
EBITDA
961.05
556.87
72.58%
707.67
818.66
-13.56%
702.22
804.39
-12.70%
726.37
646.46
12.36%
EBIDTM
21.82%
15.06%
17.66%
20.92%
17.50%
19.70%
18.44%
18.34%
Other Income
95.36
40.01
138.34%
78.53
52.93
48.37%
132.57
113.33
16.98%
170.11
151.38
12.37%
Interest
44.78
35.20
27.22%
44.19
9.15
382.95%
44.37
42.02
5.59%
35.09
27.86
25.95%
Depreciation
510.28
284.82
79.16%
293.13
522.35
-43.88%
281.90
302.22
-6.72%
241.00
213.43
12.92%
PBT
501.35
199.34
151.50%
448.88
340.09
31.99%
508.52
573.48
-11.33%
620.39
556.55
11.47%
Tax
127.75
46.15
176.81%
125.68
-64.23
-
142.39
137.42
3.62%
173.71
130.77
32.84%
PAT
373.60
153.19
143.88%
323.20
404.32
-20.06%
366.13
436.06
-16.04%
446.68
425.78
4.91%
PATM
8.48%
4.14%
8.06%
10.33%
9.13%
10.68%
11.34%
12.08%
EPS
4.56
2.22
105.41%
4.12
4.98
-17.27%
4.68
5.25
-10.86%
5.60
5.08
10.24%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
5,359.52
4,960.60
Net Sales Growth
7.51%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
17.99%
8.04%
 
Cost Of Goods Sold
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
2,452.98
2,347.40
Gross Profit
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
2,906.54
2,613.20
GP Margin
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
54.23%
52.68%
Total Expenditure
13,265.10
12,329.33
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
4,286.56
4,215.55
Power & Fuel Cost
-
298.82
251.73
245.92
228.28
218.63
233.12
235.35
198.55
92.15
91.71
% Of Sales
-
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
1.72%
1.85%
Employee Cost
-
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
289.59
242.91
% Of Sales
-
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
5.40%
4.90%
Manufacturing Exp.
-
1,220.67
1,192.77
1,596.79
737.11
644.42
541.58
583.18
627.94
708.39
676.85
% Of Sales
-
8.05%
8.29%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
13.22%
13.64%
General & Admin Exp.
-
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
288.71
231.05
193.89
% Of Sales
-
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
4.31%
3.91%
Selling & Distn. Exp.
-
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
326.48
339.15
% Of Sales
-
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
6.09%
6.84%
Miscellaneous Exp.
-
595.99
645.54
83.99
497.67
441.10
355.12
194.07
111.96
185.92
339.15
% Of Sales
-
3.93%
4.48%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
3.47%
6.52%
EBITDA
3,097.31
2,826.38
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
1,072.96
745.05
EBITDA Margin
18.93%
18.65%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
20.02%
15.02%
Other Income
476.57
357.65
228.69
208.21
165.55
265.37
222.14
139.52
91.68
353.50
354.49
Interest
168.43
114.23
159.38
206.63
168.29
145.74
33.91
38.34
25.10
28.30
52.23
Depreciation
1,326.31
1,322.82
1,322.93
754.22
504.71
372.64
330.48
312.22
273.33
167.07
151.79
PBT
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
1,231.09
895.52
Tax
569.53
250.11
179.76
331.59
400.03
463.38
544.31
306.51
195.22
243.50
124.50
Tax Rate
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
18.36%
13.90%
PAT
1,509.61
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
1,082.59
771.02
PAT before Minority Interest
1,544.87
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
1,082.59
771.02
Minority Interest
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
0.00
0.00
PAT Margin
9.23%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
20.20%
15.54%
PAT Growth
6.36%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
-10.65%
40.41%
 
Unadjusted EPS
18.96
17.53
12.52
16.93
14.71
17.29
19.24
14.25
12.32
13.70
9.92

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
5,910.57
4,347.80
Share Capital
161.02
160.90
160.68
160.59
160.58
160.58
160.58
160.58
160.58
155.46
Total Reserves
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
5,749.99
4,192.34
Non-Current Liabilities
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
184.22
1,104.39
Secured Loans
0.00
0.00
207.00
287.09
317.44
0.00
0.00
15.00
0.41
2.79
Unsecured Loans
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
4.66
937.45
Long Term Provisions
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
0.00
0.00
Current Liabilities
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
2,525.63
2,112.37
Trade Payables
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
720.88
805.41
757.43
Other Current Liabilities
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
235.28
192.56
255.44
Short Term Borrowings
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
0.00
0.00
Short Term Provisions
630.19
426.43
324.42
382.04
264.91
232.00
221.29
219.32
1,527.66
1,099.50
Total Liabilities
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56
Net Block
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
2,011.17
1,992.49
Gross Block
13,042.25
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
2,897.26
2,693.29
Accumulated Depreciation
2,816.17
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
886.09
700.80
Non Current Assets
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
2,696.41
2,359.84
Capital Work in Progress
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
684.24
366.32
Non Current Investment
157.66
137.36
176.35
249.76
397.14
415.69
328.59
367.18
1.00
1.03
Long Term Loans & Adv.
514.96
543.67
426.18
1,860.78
1,552.40
978.96
865.38
841.20
0.00
0.00
Other Non Current Assets
255.71
210.06
176.54
168.39
151.74
154.88
38.95
30.98
0.00
0.00
Current Assets
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
5,924.01
5,204.72
Current Investments
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
245.41
79.02
Inventories
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
1,512.58
1,398.32
Sundry Debtors
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
1,566.63
1,852.86
Cash & Bank
965.61
638.27
871.40
564.26
175.76
143.01
90.46
95.97
62.06
53.39
Other Current Assets
1,599.13
418.17
437.05
145.60
630.63
468.31
622.17
726.59
2,537.33
1,821.13
Short Term Loans & Adv.
1,122.86
807.84
786.12
713.07
595.13
463.21
459.94
533.77
2,387.57
1,797.68
Net Current Assets
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
3,398.38
3,092.35
Total Assets
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
1,043.03
374.83
PBT
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
1,326.09
896.84
Adjustment
1,298.59
1,374.42
950.85
630.05
552.80
283.82
396.66
288.84
146.53
252.60
Changes in Working Capital
-783.25
235.44
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
-173.82
-708.54
Cash after chg. in Working capital
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
1,298.80
440.90
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
-255.77
-64.75
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-1.32
Cash From Investing Activity
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
-562.75
-580.06
Net Fixed Assets
-495.82
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
-520.07
-624.70
Net Investments
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
-183.78
13.43
Others
-7.10
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
141.10
31.21
Cash from Financing Activity
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
-471.61
178.92
Net Cash Inflow / Outflow
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
8.67
-26.31
Opening Cash & Equivalents
610.35
858.15
545.84
175.76
143.01
90.46
95.97
62.06
53.39
79.70
Closing Cash & Equivalent
853.46
610.35
858.15
564.26
175.76
143.01
90.46
95.97
62.06
53.39

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
175.92
155.15
142.23
133.38
124.79
112.21
95.03
82.91
73.50
55.82
ROA
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
13.38%
11.60%
ROE
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
21.14%
19.07%
ROCE
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
24.22%
19.82%
Fixed Asset Turnover
1.25
1.36
1.40
1.26
1.47
1.69
1.61
1.79
1.94
2.05
Receivable days
68.17
61.60
57.62
57.94
58.66
70.11
77.94
87.29
115.32
118.45
Inventory Days
90.71
91.41
100.43
106.36
93.68
92.19
96.16
97.61
98.17
91.54
Payable days
55.61
46.96
48.81
52.17
44.93
48.58
50.51
56.11
69.48
59.02
Cash Conversion Cycle
103.26
106.05
109.24
112.14
107.41
113.72
123.59
128.78
144.01
150.98
Total Debt/Equity
0.29
0.33
0.46
0.16
0.12
0.11
0.00
0.09
0.00
0.22
Interest Cover
15.61
8.67
9.36
10.83
13.90
62.79
38.76
47.31
47.86
18.15

News Update:


  • Cipla to acquire 26% stake in AMPSolar Power Systems
    24th May 2019, 09:10 AM

    The company will acquire and maintain 26% stake on a fully diluted basis in AMPSolar

    Read More
  • Cipla reports over 2-fold jump in Q4 consolidated net profit
    22nd May 2019, 14:38 PM

    Total consolidated income of the company rose 20.37% at Rs 4,499.34 crore for quarter ended March 31, 2019

    Read More
  • Cipla gets nod to raise funds upto Rs 3000 crore via NCDs
    22nd May 2019, 14:13 PM

    The Board of directors of the company at its meeting held on May 22, 2019 has approved for the same

    Read More
  • CCI dismisses complaint against Cipla, BCDA
    21st May 2019, 10:33 AM

    The complainant had alleged that despite placement of repeated orders, Cipla had stopped the supply of medicines at the behest of BCDA

    Read More
  • USFDA conducts inspection at Cipla’s Indore facility
    18th May 2019, 08:47 AM

    The inspection ended with zero observations

    Read More
  • Cipla set for phased launch of generic cinacalcet hydrochloride tablets
    3rd May 2019, 11:48 AM

    Cinacalcet tablets are indicated for the treatment of secondary HPT in adult patients with CKD on dialysis

    Read More
  • Cipla gets approval from USFDA for Ambrisentan Tablets
    30th Apr 2019, 09:38 AM

    The US Sales of Letairis Tablets USP stood at $943 million in 2018

    Read More
  • Cipla's arm acquires 30% stake in Brandmed
    30th Apr 2019, 09:28 AM

    Out of the total upfront cash consideration payment of ZAR 65 million, ZAR 50 million has been paid

    Read More
  • Cipla’s arm to acquire 30% stake in Brandmed
    17th Apr 2019, 10:44 AM

    The company will also pay certain milestone payment for the stake acquisition over a period of three years

    Read More
  • Cipla’s arm inks definitive agreement with Pulmatrix
    16th Apr 2019, 09:01 AM

    Cipla Technologies will make an upfront payment of $22 million to Pulmatrix in exchange for assignment of all rights for Pulmazole

    Read More
  • Cipla launches Niveoli HFA inhaler for adults
    12th Apr 2019, 09:15 AM

    The latest offering from Cipla in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases

    Read More
  • Cipla gets EIR from USFDA for facility at Goa
    5th Apr 2019, 09:32 AM

    The inspection was carried out by USFDA from January 26, 2019 to January 28, 2019

    Read More
  • Cipla’s arm signs binding term sheet with Pulmatrix
    2nd Apr 2019, 08:52 AM

    Entry into a definitive agreement is contingent upon Pulmatrix raising additional funds from the market

    Read More
  • Cipla receives 8 GMP observations for Kurkumbh Plant
    1st Apr 2019, 09:21 AM

    The Company has received 10 observations pertaining to the PAI for a novel technology product slated for approval beyond 2024

    Read More
  • Cipla's arm completes acquisition of stake in Wellthy Therapeutics
    11th Mar 2019, 09:00 AM

    The company has completed transaction representing an acquisition of 11.71% stake in Wellthy

    Read More
  • Cipla to launch generic Cinacalcet hydrochloride tablets
    6th Mar 2019, 09:13 AM

    Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease

    Read More
  • Cipla wins portion of state ARV tender
    19th Feb 2019, 09:23 AM

    The contract is effective from July 01, 2019 and is valid for three years

    Read More
  • Cipla's arm to acquire 11.71% stake in Wellthy Therapeutics
    19th Feb 2019, 09:02 AM

    The transaction expected to be completed before March 10, 2019

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.